Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glucuronic Acid SCHEMBL17233397 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL12189507 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL5974 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL6759131 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL23929292 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL598674 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Mucic Acid SCHEMBL23388836 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL23929291 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Mucic Acid SCHEMBL23388833 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 | |
| Glucuronic Acid SCHEMBL2559030 | 1.00 | PDE4A (0.46) | PDE4ATSHRCYP2C9ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572722-A1 | ALGINATE TAMPON AND PRODUCTION METHOD | Vyld GmbH (DE) | 2025-06-25 | — | — | EP | claimed |
| CN-119707132-A | Antibacterial scale inhibitor, compounding method and application thereof | 宁波酶赛生物工程有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4392465-A1 | DIBLOCK POLYMER | Norwegian University of Science and Technology (NTNU) (NO) | 2024-07-03 | — | — | EP | claimed |
| CN-118251423-A | Diblock polymer | 挪威科技大学 | 2024-06-25 | — | — | CN | claimed |
| WO-2024038205-A1 | ALGINATE TAMPON AND PRODUCTION METHOD | VYLD GMBH (DE) | 2024-02-22 | — | — | WO | claimed |
| CN-116391036-A | Cleaning compositions containing alginate lyase | 宝洁公司 | 2023-07-04 | — | — | CN | claimed |
| US-20230121990-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF GLUCOSE OXIDATION PRODUCTS | SOLUGEN, INC. (US) | 2023-04-20 | — | — | US | claimed |
| WO-2023025943-A1 | DIBLOCK POLYMER | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2023-03-02 | — | — | WO | claimed |
| US-20230024853-A1 | AEROSOL-GENERATING MATERIAL COMPRISING AN AMORPHOUS SOLID COMPRISING METHOD AND CALCIUM-CROSSLINKED ALGINATE | Nicoventures Trading Limited (GB) | 2023-01-26 | — | — | US | claimed |
| EP-4114930-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF GLUCOSE OXIDATION PRODUCTS | Solugen, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| CN-115397977-A | Compositions and methods for producing glucose oxidation products | 索鲁根公司 | 2022-11-25 | — | — | CN | claimed |
| EP-4064866-A1 | AEROSOL-GENERATING MATERIAL COMPRISING AN AMORPHOUS SOLID COMPRISING METHOL AND CALCIUM-CROSSLINKED ALGINATE | Nicoventures Trading Limited (GB) | 2022-10-05 | — | — | EP | claimed |
| CN-114901264-A | Pharmaceutical preparation | 卡里亚制药控股有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-11331408-B2 | Class of anti-adhesion hydrogels with healing aspects | BVW HOLDING AG (CH) | 2022-05-17 | — | — | US | claimed |
| US-12617905-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| WO-2026089719-A1 | DNA VECTORS HAVING SPECIALIZED SECONDARY STRUCTURES FOR USE IN TREATING HYPOPHOSPHATASIA | RAMPART BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090562-A1 | DNA VECTORS HAVING SPECIALIZED SECONDARY STRUCTURES FOR USE IN TREATING HYPOPHOSPHATASIA | RAMPART BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-2036533-A1 | Curable Dental Retraction Composition, Method of Production and Use thereof | 3M Innovative Properties Company (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008021740-A2 | CURABLE DENTAL RETRACTION COMPOSITION, METHOD OF PRODUCTION AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1886659-A1 | Curable dental retraction composition, method of production and use thereof | 3M Innovative Properties Company (US) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617905-B2 | Crosslinked alginic acid | ALG1, ANXA6, HEXB | PDE4A 3986/4885TSHR 4550/4885CYP2C9 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.